Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.49 |
| ▸ | NPC1 | O15118 | 7/20 | 0.46 |
| ▸ | RAB9A | P51151 | 6/20 | 0.46 |
| ▸ | MAPT | P10636 | 7/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21603764 | 0.83 | ALDH1A1 (0.54) | ALDH1A1NPC1RAB9AMAPTLMNA | |
| SCHEMBL21604124 | 0.81 | ALDH1A1 (0.42) | ALDH1A1NPC1RAB9AMAPTLMNA | |
| SCHEMBL27415416 | 0.80 | NPC1 (0.32) | ALDH1A1NPC1RAB9A | |
| SCHEMBL27415413 | 0.80 | EPHX2 (0.36) | NPC1RAB9AKMT2A | |
| SCHEMBL21597427 | 0.68 | TBXAS1 (0.46) | ALDH1A1NPC1RAB9AMAPTLMNA | |
| SCHEMBL21597801 | 0.68 | TP53 (0.40) | ALDH1A1NPC1RAB9AMAPTLMNA | |
| SCHEMBL3348661 | 0.67 | ALDH1A1 (0.69) | ALDH1A1NPC1RAB9AMAPTLMNA | |
| SCHEMBL21597674 | 0.66 | TP53 (0.44) | ALDH1A1NPC1RAB9AMAPTLMNA | |
| SCHEMBL21603763 | 0.65 | TP53 (0.39) | ALDH1A1NPC1RAB9AMAPTLMNA | |
| SCHEMBL21597854 | 0.65 | TP53 (0.41) | ALDH1A1NPC1RAB9ALMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | ALDH1A1 233/4885NPC1 185/4885RAB9A 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.